TY - JOUR AU - Bahig, Houda AU - Aubin, Francine AU - Stagg, John AU - Gologan, Olguta AU - Ballivy, Olivier AU - Bissada, Eric AU - Nguyen-Tan, Felix-Phuc AU - Soulières, Denis AU - Guertin, Louis AU - Filion, Edith AU - Christopoulos, Apostolos AU - Lambert, Louise AU - Tehfe, Mustapha AU - Ayad, Tareck AU - Charpentier, Danielle AU - Jamal, Rahima AU - Wong, Philip PY - 2019 DA - 2019/01/14 TI - Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma JO - BMC Cancer SP - 68 VL - 19 IS - 1 AB - The efficacy of immunotherapy targeting the PD-1/PD-L1 pathway has previously been demonstrated in metastatic head and neck squamous cell carcinoma (HNSCC). Stereotactic Body Radiotherapy (SBRT) aims at ablating metastatic lesions and may play a synergistic role with immunotherapy. The purpose of this study is to assess the safety and efficacy of triple treatment combination (TTC) consisting of the administration of durvalumab and tremelimumab in combination with SBRT in metastatic HNSCC. SN - 1471-2407 UR - https://doi.org/10.1186/s12885-019-5266-4 DO - 10.1186/s12885-019-5266-4 ID - Bahig2019 ER -